Symbicort Turbuhaler is a combination product containing a long-acting ß2 agonist with a bronchodilating action that is the mainstay of drug-based COPD therapy, and an inhaled corticosteroid, which reduces exacerbations of COPD.
The dry-power inhaler can reduce exacerbations of COPD and has a rapid onset of action, substantially contributing to an improved quality-of-life (QOL) for COPD patients.
The COPD patients are supposed to inhale Symbicort Turbuhaler four times per day with a daily dose is 640µg of budesonide and 18µg of formoterol fumarate hydrate.
The product was launched in January 2010 as a twice-daily, dry-power inhaler combination product for the treatment of bronchial asthma in Japan.